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INTRODUCTION
Multiple sclerosis (MS) is a chronic
demyelinating inflammatory disease of the
central nervous system (CNS) with multi-
factorial pathogenesis that includes genetic
and environmental factors. A primary
brain tumor is a neoplasm developing from
the cells of the brain. There is high het-
erogeneity of primary brain tumors (about
100 different types); however, most of them
develop from the glial cells.
Although several types of brain tumors
have been widely described in associa-
tion with MS (1–20), including astrocy-
toma (5, 9), oligodendroglioma (12, 17),
and glioblastoma (3, 11, 14, 18), it is not
clear whether their occurrence is acciden-
tal or consequent to causal events. More-
over, it is not completely defined if MS and
brain tumors, when associated, have a dif-
ferent course. The true incidence of brain
tumors in MS patients is difficult to define
because the diagnosis of a brain tumor in
MS patients may seem more frequent than
in the general population due to frequent
neuroimaging scans performed in these
patients (21). At the same time, pseudo-
tumoral MS lesions may resemble gliomas,
and conversely, early stage gliomas may
resemble MS. Brain tumors in MS patients
may be diagnosed later or even post-
mortem (22), especially in patients with
progressive MS, since the new symptoms
may be attributed to the gradual clinical
progression of MS rather than to the slow
growing of tumor itself (23). A recent study
reported that MS patients have a decreased
overall cancer risk, but an increased risk
for brain tumor (24). If immunosuppres-
sive treatment for MS might promote can-
cerogenesis is still matter of debate, it is
difficult to explain on this basis why MS
patients have a decreased overall cancer
risk and an increased risk only for brain
and genitourinary tract tumors (24). A
successive systematic analysis showed no
increased or decreased risks for glioma
in MS patients, while an increased risk
was found for meningioma, as a result
of incidental findings (25). Moreover, sev-
eral autoimmune diseases influence nega-
tively the survival in glioma and menin-
gioma, likely due to pre-existent disability
or treatment limitations (25).
DIFFERENTIAL DIAGNOSIS BETWEEN
MS AND BRAIN TUMORS
A first issue emerging in case of con-
currence of MS and brain tumors is the
differential diagnosis since MS plaques
may resemble gliomas and vice-versa (26).
Although brain tumors associated with MS
have their usual distribution at frontal
and temporal lobes (27), the localiza-
tion criteria are not helpful for the dif-
ferential diagnosis. Therefore, the appear-
ance of uncommon neurological symp-
toms in MS patients should suggest the
need for more extensive investigations in
order to exclude overlapping pathologies
(28). In addition to brain tumors, the
differential diagnosis of pseudo-tumoral
brain lesions includes infectious, neo-
plastic (in particular primary CNS lym-
phomas and metastatic cancers), congen-
ital, metabolic or vascular diseases, and
non-MS idiopathic inflammatory demyeli-
nating diseases as well (for instance,
neuromyelitis optica, opticospinal MS in
Asian populations, acute disseminated
encephalomyelitis) (29). They differ from
MS in course, pathophysiology, treatment,
and prognosis. In 2008, the Task Force on
Differential Diagnosis in MS has defined
major, intermediate, and minor red flags
consisted in informative symptoms, signs,
and assays indicative, respectively, of non-
MS diagnosis, uncertainty or possibility
that an MS diagnosis is not excluded
(29). The major red flags, for example, for
lymphoma, are represented by persistent
Gd-enhancement, continued enlargement
of lesions, simultaneous enhancement of
all lesions, marked asymmetry of white
matter lesions, headache, or meningismus.
Among the diagnostic tools that have
been proposed to differentiate MS from
tumors, there are also some blood indi-
cators such as inflammatory transcription
factors of the peripheral blood mononu-
clear cells (18). However, they are more use-
ful in expressing patients’ immunological
status than in making a proper differential
diagnosis between MS and brain tumors.
To date, the non-conventional MRI tech-
niques such as spectroscopy, positron emis-
sion tomography, and CNS biopsy remain
the most useful tools for the differential
diagnosis.
POSSIBLE CAUSAL RELATIONSHIP
BETWEEN BRAIN TUMORS AND MS
Whether the concurrence of MS and
glioma may be explained by causal rela-
tionship or by coincidence is still mat-
ter of debate (17, 25). In 1973, it was
observed that despite the rare concur-
rence of such relatively common con-
ditions some pathological features, espe-
cially the frequent contiguous relationship
between tumor and plaque, suggested a
closer association between these patholo-
gies (30). It was hypothesized that in some
MS patients an unknown factor, hereditary
or acquired, may stimulate the neoplas-
tic transformation of reactive astrocytes.
Moreover, it was supposed a causative role
for a bipotential cytolytic-oncogenic agent
such as Papova virus (30). Almost 20 years
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later, another study, based on the most
extensive literature, came to similar con-
clusions (31). A transformation of a mega-
plaque into an ependymoma added new
evidence in favor to a cause–effect rela-
tionship between MS and brain tumors
(32). It can be hypothesized that MS lesions
may transform into a tumor likely due to
circumscribed increased proliferation ratio
induced by MS remyelinating processes
since the neurotropic growth factors pro-
moting the proliferation and survival of
oligodendrocytes have the beneficial effect
on the clinical, pathological, and molecular
manifestations of autoimmune demyelina-
tion in experimental models (33, 34). It
was also found a re-expression of a devel-
opmental gene in chronic lesions with the
highest levels of their products correlating
with remyelination (35). The recapitula-
tion of ontogenetic events during myelin
repair has been supposed as normal adult
CNS and non-MS material showed very
low levels of such gene products, while
fetal human CNS tissue showed high levels.
Therefore, the possibility of common rare
underlying genetic factors in both tumors
and MS is possible, but so far there are no
sufficient data to definitely confirm it. Fur-
thermore, owing to high heterogeneity of
primary brain tumors, the research on their
genetic alterations is not simple. Interest-
ingly, the recently identified MS risk genes
mainly belong to the immune system (36),
and alterations in innate immunity-related
genetic regions have been associated with
an increased risk of adult glioma (37). It
may be also hypothesized that aberrant epi-
genetic mechanisms, such as DNA methy-
lation and histone protein modifications,
could be involved in both MS and tumor
pathogenesis (38). Methylated gene pro-
moters are silenced, while unmethylated
ones can be active reflecting, albeit impre-
cisely, gene expression. Certain regions of
the brain in MS patients show abnormally
methylated genes with a specific profile
or decreased methylation, for example, of
cytosine of the gene encoding the myelin
enzyme peptidylarginine deiminase-2 pro-
moter in MS normal-appearing white mat-
ter (39). Still more, DNA methylation is
altered in tumors and may represent a pre-
dictive factor of response to specific drugs.
In particular, the O6-methylguanine-DNA
methyltransferase promoter hypermethy-
lation was found to be strongly associated
with partial or complete clinical response
(40–42). However, no possible causal epi-
genetic mechanisms between brain tumors
and MS could be inferred by these limited
data.
Finally, it is possible to speculate that
a common viral agent is involved in
the pathogenesis of these diseases. After
30 years from the first supposition of a
possible Papova virus role in both dis-
orders (30), the post-mortem examina-
tion of an immunocompetent patient with
MS plaques and a glioblastoma multi-
forme provided molecular evidence of
the association of human polyomavirus
JC virus (JCV) of Papova virus family
with these concurrent pathologies (14).
PCR analysis revealed the presence of viral
DNA in demyelinated plaques and within
the tumor, while immunohistochemistry
showed the detection of the viral early
protein, T-antigen, and the cellular tumor
suppressor protein, p53, only in the nuclei
of neoplastic cells. Conversely, the expres-
sion of T-antigen, but not of p53, was
observed in astrocytes and neuronal cells
of the cortex juxtaposed to the MS plaque.
No productive replication of JCV was iden-
tified in both tumor and MS lesions since
the examination of viral late gene expres-
sion by immunohistochemistry showed no
evidence for viral capsid proteins. Further-
more, some authors detected the presence
of JCV in samples derived from several
types of neural and non-neural human
tumors (43–50), and several studies high-
lighted its potential role in a broad range of
animal models and human carcinogenesis
(51–54).
JC virus was identified as the eti-
ologic agent of progressive multifocal
leukoencephalopathy, first diagnosed only
in immunocompromised patients or those
suffering from leukemia, but now repre-
senting a serious complication of Natal-
izumab treatment in MS (55, 56). JCV is
very common in the general population
infecting 70–90% of humans (57), and a
higher rate of JCV seroconversion com-
pared to than expected has been observed
in MS patients treated with Natalizumab
(58). JC viral genome has been detected
in normal brain tissue (59), therefore,
the latent JCV-DNA antigens expressed
at low levels in the CNS have been pro-
posed as possible targets of pathogenetic
immune response in MS (60). Initially,
the JCV-DNA was found neither in the
urine (61) nor in the brain tissue (62) of
MS patients. However, more recent studies
showed the presence of JCV-DNA in both
CSF (63, 64) and blood (65) in MS patients
(although in a low percentage) and not in
controls.
Moreover, novel clinical entities with-
out typical PML lesions caused by JCV
variants infecting cerebellar granule cell
neurons and cortical pyramidal neurons as
well as JCV meningitis have been recently
discovered (66).
Therefore, JCV might be a feasible eti-
ological candidate for both MS and brain
tumors due to its ability to persist in the
latent state mainly in myelin-producing
oligodendrocytes and to its oncogenic
capacity. However, JCV presence might still
simply reflect the subclinical immunodefi-
ciency of cancer patients or MS patients
treated with immunosuppressive drugs.
THERAPY OF ASSOCIATED MS AND
BRAIN TUMORS
There are no trials on the treatment of asso-
ciated cases of MS and brain tumors owing
to their rarity. The data here reported
represent case reports and experimental
observations.
It should not seem strange that the
immunosuppressive treatments given for
neoplasms may reduce disease activity in
MS. In a patient of ours with MS and oligo-
dendroglioma, MS activity significantly
reduced both clinically and at MRI during
the 2-year treatment with temozolomide
(personal unpublished data).
Although the safety of radiotherapy for
MS course was described in one case report
(67), the negative effects of surgery and
radiotherapy on MS, due to the liberation
of brain-specific antigens triggering disim-
mune reactions, have also been reported
(68). A vast review on MS relapses consid-
ered cranial radiation as their promoting
factor (69).
Furthermore, a sphingosine analog
FTY720, which downregulates the expres-
sion of sphingosine-1-phosphate receptors,
is not only effective in MS (70) but also
causes in vitro apoptosis of brain tumor
stem cells derived from human glioblas-
toma tissue (71). Also dimethyl-fumarate,
demonstrated to be effective in treatment
of MS (72), appears to act on malig-
nant brain neoplasms in vitro by reducing
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the proliferation rate, generating cell lysis,
decreasing the expression of NF-κB, and
restricting the growth of CD133 cells in
gliomas (73).
CONCLUSION
Although the co-existence of MS and brain
tumors has been long described, many
doubts regarding their possible causal asso-
ciation persist. JCV is of significant interest
in this issue due to its ability to latent persist
in the CNS and to its experimental neu-
rooncogenic potential. Since MS is caused
by putative CNS autoimmune mechanisms
whereas brain neoplasms may be depen-
dent on a subclinical immunosuppressive
state, these pathologies can coexist only in
particular situations. It can be hypothe-
sized that these conditions may occur dur-
ing the remyelinating processes coinciding
with a decline of the CNS immune reaction
and with the production of growth factors
in the effort to repair the damage, thus
favoring a hypothetical JCV-related cell
neoplastic transformation in genetically or
environmentally induced susceptible indi-
viduals. Studying with special care, the
patients affected by both diseases, which
apparently locate at the opposite ends of
immunosurveillance, could allow to find
the key to their pathogenesis.
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